The role of inflammation in CNS injury and disease
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
For many years, the central nervous system (CNS) was considered to be ‘immune privileged’, neither susceptible to nor contributing to inflammation. It is now appreciated that the CNS does exhibit features of inflammation, and in response to injury, infection or disease, resident CNS cells generate inflammatory mediators, including proinflammatory cytokines, prostaglandins, free radicals and complement, which in turn induce chemokines and adhesion molecules, recruit immune cells, and activate glial cells. Much of the key evidence demonstrating that inflammation and inflammatory mediators contribute to acute, chronic and psychiatric CNS disorders is summarised in this review. However, inflammatory mediators may have dual roles, with detrimental acute effects but beneficial effects in long‐term repair and recovery, leading to complications in their application as novel therapies. These may be avoided in acute diseases in which treatment administration might be relatively short‐term. Targeting interleukin (IL)‐1 is a promising novel therapy for stroke and traumatic brain injury, the naturally occurring antagonist (IL‐1ra) being well tolerated by rheumatoid arthritis patients. Chronic disorders represent a greater therapeutic challenge, a problem highlighted in Alzheimer's disease (AD); significant data suggested that anti‐inflammatory agents might reduce the probability of developing AD, or slow its progression, but prospective clinical trials of nonsteroidal anti‐inflammatory drugs or cyclooxygenase inhibitors have been disappointing. The complex interplay between inflammatory mediators, ageing, genetic background, and environmental factors may ultimately regulate the outcome of acute CNS injury and progression of chronic neurodegeneration, and be critical for development of effective therapies for CNS diseases. British Journal of Pharmacology (2006) 147, S232–S240. doi:10.1038/sj.bjp.0706400
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As various neurological and psychiatric diseases have been associated with neuroinflammation in some post-mortem studies,183, 184, 185”
From Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review (2018) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Stroke is caused by ischaemia, leading to inflammation [900] and to the formation of ROS and other damaging free radicals [901] in the brain”
The cited source says what the claim attributes to it.
In the citing paper
“These processes induce adhesion molecules and, in order, mobilize immune and glial cells in a parallel and synergistic way (94, 126 -128).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [127]
In the citing paper
“Thus, although this is not the focus of the present more physiologically based review, we recognise that many of relationships between ROSs and oxidative stress and overt progressive diseases may be mediated via the inflammatory signalling pathways involved in 'innate immunity' [900,1991-1993].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Reactive Astrocytes Protect Tissue and Preserve Function after Spinal Cord Injury
Faulkner, J. R., Herrmann, J. E., Woo, M. J., Tansey, K. E., Doan, N. B., & Sofroniew, M. V. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3547-03.2004 · Cited by 1,598 · cited 1×
“…for repair and recovery, but in fact this increases neuronal loss from the injury site and inhibits repair of the BBB and axonal remyelination (Faulkner et al., 2004), partly because astrocytes produce neurotrophic factors such as nerve growth factor and brain-derived growth factor that are…”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“Although other epidemiological studies also suggest a beneficial role for antiinflammatory agents in AD (McGeer et al., 1996), the general view from prospective trials of nonsteroidal inflammatory drugs (NSAIDs) is that they are disappointingly variable.”
BackgroundTNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
Interleukin 1 in the brain: biology, pathology and therapeutic target
Rothwell, N. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01661-1 · Cited by 671 · cited 3×
“IL-1 was discovered as an important endogenous pyrogen, and is now recognised as the ‘prototypic inflammatory cytokine’ (reviewed by Rothwell & Luheshi, 2000).”
BackgroundInfluentialSelf-citationPerry, V. H. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.01.004 · Cited by 560 · cited 2×
“…metalloproteinase and iNOS activities, and breakdown of the BBB. Complications of its use however include inhibition of remyelination in MS models, and observations that microglial activation may be associated with anti-inflammatory cytokine expression rather than proinflammatory (Perry, 2004).”
BackgroundInflammation and the Degenerative Diseases of Aging
McGEER, P. L., & McGEER, E. G. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.007 · Cited by 518 · cited 1×
“The complement cascade is activated, and mRNAs for complement proteins are upregulated in PD (and AD) to a greater extent than in peripheral inflammatory diseases such as rheumatoid arthritis (reviewed by McGeer & McGeer, 2004).”
BackgroundScherbel, U., Raghupathi, R., Nakamura, M., Saatman, K. E., Trojanowski, J. Q., Neugebauer, E., Marino, M. W., & McIntosh, T. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8721 · Cited by 415 · cited 1×
“…injury, the TNFa knockout mice show less behavioural impairment than the wild-type controls, but while the wild-type mice recovered in the weeks following injury, the knockout mice did not, remaining significantly impaired both in terms of histological damage and behaviour (Scherbel et al., 1999).”
BackgroundNew Insights into the Biology of the Acute Phase Response
Suffredini, A. F., Fantuzzi, G., Badolato, R., Oppenheim, J. J., & O'Grady, N. P. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020563913045 · Cited by 391 · cited 1×
“This represents another host defence mechanism which can limit proliferation of invading pathogens (Suffredini et al., 1999).”
BackgroundVezzani, A., Moneta, D., Richichi, C., Aliprandi, M., Burrows, S. J., Ravizza, T., Perego, C., & De Simoni, M. G. (2002) · Epilepsia · doi:10.1046/j.1528-1157.43.s.5.14.x · Cited by 386 · cited 1×
“Exogenous IL-1b enhances chemically induced seizures in rats and IL-1ra inhibits motor seizures and delays their onset (see Vezzani et al., 2002).”
BackgroundThe many faces of tumor necrosis factor in stroke
Hallenbeck, J. M. (2002) · Nature Medicine · doi:10.1038/nm1202-1363 · Cited by 367 · cited 1×
“However, a significant reduction in infarct size has been observed in mice treated with TNFa prior to the insult, suggesting dual neurotoxic and neuroprotective roles for this cytokine (Hallenbeck, 2002).”
BackgroundInterleukin-6 expression and regulation in astrocytes
Van Wagoner, N. J., & Benveniste, E. N. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00187-3 · Cited by 363 · cited 1×
“IL-6 signals through a specific receptor (IL-6R) to stimulate various signalling pathways which lead to gene activation (Van Wagoner & Benveniste, 1999).”
BackgroundNovel anti-inflammatory therapy for Parkinson's disease
Gao, H.-M., Liu, B., Zhang, W., & Hong, J.-S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00176-7 · Cited by 324 · cited 1×
“A role of inflammation has been strongly implicated (reviewed by Gao et al., 2003), and activated microglia are found close to degenerating substantia nigral neurones of patients with PD. Inhibiting microglial activation with agents such as naloxone, an opioid receptor antagonist, or the…”
BackgroundInfectious causes of multiple sclerosis
Giovannoni, G., Cutter, G. R., Lunemann, J., Martin, R., Münz, C., Sriram, S., Steiner, I., Hammerschlag, M. R., & Gaydos, C. A. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70577-4 · Cited by 295 · cited 1×
“…factors may be as important as genetic predisposition to the development of MS, and it has been proposed that the disease may be triggered in genetically susceptible individuals by viral infection, although no virus has been isolated from postmortem brain tissue from MS patients (Gilden, 2005).”
BackgroundTheories of schizophrenia: a genetic-inflammatory-vascular synthesis
Hanson, D. R., & Gottesman, I. I. (2005) · BMC Medical Genetics · doi:10.1186/1471-2350-6-7 · Cited by 276
Yoshihara, T., Ishigaki, S., Yamamoto, M., Liang, Y., Jun, Niwa, I., Takeuchi, H., Doyu, M., & Sobue, G. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00683.x · Cited by 275 · cited 1×
“ALS, a rapidly progressing motor neurone disease, is associated with mutation of superoxide dismutase (SOD1) gene, and mice that overexpress mutant SOD1 show upregulation of TNFa (Yoshihara et al., 2002), suggesting activation of microglia.”
BackgroundRole of nitric oxide after brain ischaemia
Moro, M. A., Cárdenas, A., Hurtado, O., Leza, J. C., & Lizasoain, I. (2004) · Cell Calcium · doi:10.1016/j.ceca.2004.02.011 · Cited by 266 · cited 1×
“In particular, nitric oxide (NO) is emerging as an effector of neurodegeneration (Moro et al., 2004).”
BackgroundRaivich, G., & Banati, R. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.06.006 · Cited by 248 · cited 1×
“Many inflammatory mediators are upregulated in MS and associated with the demyelinating lesions (reviewed by Raivich & Banati, 2004).”
BackgroundTumor necrosis factor‐α inhibits seizures in mice via p75 receptors
Balosso, S., Ravizza, T., Perego, C., Peschon, J., Campbell, I. L., De Simoni, M. G., & Vezzani, A. (2005) · Annals of Neurology · doi:10.1002/ana.20480 · Cited by 207 · cited 1×
“Transgenic mice that overexpress TNFa are less susceptible to seizure induction than wild-type animals, and mice which lack TNFa p75 receptors suffer prolonged seizures (Balosso et al., 2005).”
BackgroundLow levels of circulating inflammatory cytokines—Do they affect human brain functions?
Pollmächer, T., Haack, M., Schuld, A., Reichenberg, A., & Yirmiya, R. (2002) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00004-1 · Cited by 202 · cited 1×
“There is increasing evidence for the involvement of IL-1 in sleep, feeding and memory (Pollmacher et al., 2002).”
BackgroundSamland, H., Huitron‐Resendiz, S., Masliah, E., Criado, J., Henriksen, S. J., & Campbell, I. L. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10635 · Cited by 178 · cited 1×
“In contrast, mice which overexpress IL-6 are much more sensitive to glutamatergic seizures than wild-type animals (Samland et al., 2003).”
BackgroundInfectious causes of multiple sclerosis
GILDEN, D. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70023-5 · Cited by 174
Antibody to the α4 Integrin Decreases Infarct Size in Transient Focal Cerebral Ischemia in Rats
Becker, K., Kindrick, D., Relton, J., Harlan, J., & Winn, R. (2001) · Stroke · doi:10.1161/01.str.32.1.206 · Cited by 168
Inflammation, Neurodegenerative Diseases, and Environmental Exposures
CAMPBELL, A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.008 · Cited by 163 · cited 1×
“Chronic CNS diseases have a more complex aetiology than acute injuries, and are generally multifactorial, with environmental factors and genetic background contributing to the development and progression of the disease (reviewed by Campbell, 2004).”
BackgroundTehranian, R., Andell, S., Beni, S. M., Yatsiv, I., Shohami, E., Bartfai, T., Lundkvist, J., & Iverfeldt, K. (2002) · Journal of Neurotrauma · doi:10.1089/089771502320317096 · Cited by 158 · cited 1×
“Furthermore, in a closed head injury model of TBI, mice which overexpress IL-1ra show no significant acute increase in IL-1, TNFa or IL-6 levels, and exhibit improved neurological recovery compared with wild-type animals (Tehranian et al., 2002).”
BackgroundInfectious causes of multiple sclerosis
Gilden, D. H. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)01017-3 · Cited by 157
Mycko, M. P., Papoian, R., Boschert, U., Raine, C. S., & Selmaj, K. W. (2003) · Brain · doi:10.1093/brain/awg107 · Cited by 152 · cited 1×
“Microarray analysis has revealed that many genes related to inflammatory processes are upregulated in the marginal zones of active demyelinating lesions (Mycko et al., 2003).”
BackgroundStanislaus, R., Singh, A. K., & Singh, I. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1207 · Cited by 140 · cited 1×
“Lovastatin blocks progression of experimental allergic encephalitis (a model of MS), reducing cytokine and iNOS expression, but also transmigration of monocytes, perhaps by reducing expression of a1b1 integrin (Stanislaus et al., 2001).”
BackgroundSewell, D. L., Nacewicz, B. M., Liu, F., Macvilay, S., Erdei, A., Lambris, J. D., Sándor, M., & Fábry, Z. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.06.003 · Cited by 138 · cited 1×
“Secondary damage caused by experimental brain injury is reduced in mice which lack complement C3 or complement C5, and C5a receptor antagonists reduce CNS cell loss (Sewell et al., 2004).”
BackgroundNeuroprotection by Complement (C1) Inhibitor in Mouse Transient Brain Ischemia
Simoni, M. G. D., Storini, C., Barba, M., Catapano, L., Arabia, A. M., Rossi, E., & Bergamaschini, L. C. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000046146.31247.a1 · Cited by 130 · cited 1×
“The complement cascade may also have deleterious effects in stroke; inhibition of the complement system using a C1 antagonist reduces neurological deficits and infarct volume following transient focal ischaemia (De Simoni et al., 2003).”
BackgroundSheng, Griffin, Royston, & Mrak (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00122.x · Cited by 115 · cited 1×
“Activated microglia surround the amyloid plaques that are one of the hallmarks of the disease (Sheng et al., 1998).”
BackgroundInducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling
Takemiya, T., Suzuki, K., Sugiura, H., Yasuda, S., Yamagata, K., Kawakami, Y., & Maru, E. (2003) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s1098-8823(03)00040-6 · Cited by 94 · cited 1×
“COX-2 and PG levels increase markedly following rapid seizure kindling in mice, and mice which are deficient in COX2 display reduced hippocampal seizure activity (Takemiya et al., 2003).”
BackgroundThe role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease
Everbroeck, B. V., Dewulf, E. M., Pals, P., Lübke, U., Martin, J., & Cras, P. P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00236-6 · Cited by 88
Infectious causes of multiple sclerosis
Holmøy, T., & Vartdal, F. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70054-5 · Cited by 87
Association between the interleukin-1α gene and Alzheimer’s disease: a meta-analysis
Rainero, I., Bo, M., Ferrero, M., Valfrè, W., Vaula, G., & Pinessi, L. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.011 · Cited by 81 · cited 1×
“Perhaps the most convincing evidence however for a causal role of inflammation in AD comes from many studies demonstrating associations between polymorphisms in the genes encoding members of the IL-1 family and AD (e.g. Rainero et al., 2004), particularly IL-1a.”
BackgroundAntiepileptogenic and anticonvulsant activity of interleukin-1β in amygdala-kindled rats
Sayyah, M., Beheshti, S., Shokrgozar, M. A., Eslamifar, A., Deljoo, Z., Khabiri, A., & Rohani, A. H. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.032 · Cited by 52 · cited 1×
“In a rodent amygdala kindling model of epilepsy, fully kindled seizures are inhibited by IL-1b, and daily injection of IL-1b during kindling slows the rate of kindling (Sayyah et al., 2005).”
BackgroundPiraino, P. S., Yednock, T. A., Freedman, S. B., Messersmith, E. K., Pleiss, M. A., Vandevert, C., Thorsett, E. D., & Karlik, S. J. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00273-4 · Cited by 42 · cited 1×
“A small molecule inhibitor of integrin a4 also significantly reduces inflammation and disease pathology in an animal model of MS (Piraino et al., 2002).”
BackgroundNeuroprotection by Complement (C1) Inhibitor in Mouse Transient Brain Ischemia
Simoni, M. G. D., Storini, C., Barba, M., et al. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200302000-00010 · Cited by 42
Nail-Biting Time for Trials of COX-2 Drugs
Couzin, J. (2004) · Science · doi:10.1126/science.306.5702.1673 · Cited by 40 · cited 1×
“A larger trial involving the COX-2 inhibitor Vioxx was then terminated following a dramatic increase in the incidence of cardiovascular side effects (Couzin, 2004), which is worrying for ageing AD patients who are already at high risk of heart disease.”
BackgroundPriming with Interleukin‐1β Suppresses Experimental Allergic Encephalomyelitis in the Lewis Rat
Huitinga, I., Schmidt, E. D., van der Cammen, M. J. F., Binnekade, R., & Tilders, F. J. H. (2000) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2000.00574.x · Cited by 31
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5 · cited 1×
“Patients receiving the COX-2 inhibitor or NSAID showed no slowing of cognitive decline compared with patients receiving placebo (Aisen et al., 2003).”
Result
Cited by
Pathophysiology of traumatic brain injury
Werner, C., & Engelhard, K. (2007) · British Journal of Anaesthesia · doi:10.1093/bja/aem131 · Cited by 1,712
Nita, M., & Grzybowski, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3164734 · Cited by 1,448
“Apoptotic processes are also activated by microglial cells, which release inflammatory mediators (cytokines, prostaglandins, and complement molecules) and reactive oxygen species [113].”
BackgroundInflammatory mechanisms in ischemic stroke: therapeutic approaches
Lakhan, S. E., Kirchgessner, A., & Hofer, M. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-97 · Cited by 1,072
“There is substantial evidence that activated microglial cells in response to ischemia have the potential of releasing several pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6, as well as other potential cytotoxic molecules including NO, ROS, and prostanoids [25].”
IL‐1, IL‐18, and IL‐33 families of cytokines
Arend, W. P., Palmer, G., & Gabay, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00624.x · Cited by 912
“Diseases of the central nervous system An extensive literature exists on the production of IL-1b by microglial and other cells in the brain, primarily in the hypothalamus (50, 51).”
BackgroundBlood–brain barrier breakdown as a therapeutic target in traumatic brain injury
Shlosberg, D., Benifla, M., Kaufer, D., & Friedman, A. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.74 · Cited by 897
Metadata
- Authors
- Lucas, S., Rothwell, N. J., & Gibson, R. M.
- Affiliations
- University of Manchester (GB)
- HSE Science and Research Centre (GB)
- Corresponding author
- Rothwell, Nancy J
- ORCID
- Rothwell, Nancy J
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 147
- Issue
- S1
- Pages
- S232-40
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC1760754
- OpenAlex
- W1594425991
- Cited by
- 1,272
- References
- 41
- Citations by year
- 2026: 12 · 2025: 37 · 2024: 32 · 2023: 57 · 2022: 65 · 2021: 69 · 2020: 62 · 2019: 80 · 2018: 67 · 2017: 67 · 2016: 60 · 2015: 89 · 2014: 77 · 2013: 79 · 2012: 62
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
- Keywords
- neuroinflammation, central nervous system injury, immune privilege, inflammatory cytokines, prostaglandins, free radicals, complement system, chemokines, glial activation, interleukin-1, interleukin-1 receptor antagonist, stroke, traumatic brain injury, Alzheimer's disease, anti-inflammatory therapy, neurodegeneration, aging
- MeSH terms
- Acute Disease, Animals, Brain, Central Nervous System Diseases, Chronic Disease, Craniocerebral Trauma, Humans, Inflammation, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.